Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2019

01-09-2019 | Chronic Lymphocytic Leukemia | Brief Research Article

Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells

Authors: J.-R. Romero-Macías, R. Pascual-Serra, O. Roche, F. Ruiz-Marcos, A. Serrano-Martínez, P. González-Aguado, B. Belandia, M.-J. Ruiz-Hidalgo, R. Sánchez-Prieto

Published in: Clinical and Translational Oncology | Issue 9/2019

Login to get access

Abstract

Purpose

Autophagy has lately emerged as an important biological process with implications in several hematological pathologies. Recently, a growing body of evidence supports a putative role of autophagy in chronic lymphocytic leukemia; however, no definitive clue has been established so far. To elucidate this issue, we have developed a pilot study to measure autophagic flux in peripheral blood mononuclear cells from chronic lymphocytic leukemia patients, and explored its correlation with classical clinical/analytical parameters.

Methods/patients

Thirty-three chronic lymphocytic leukemia patients participated in the study. Autophagic flux in peripheral blood mononuclear cells was determined by western blot measuring the levels of the proteins p62 and lipidated LC3. Moreover, p62 mRNA levels were analyzed by RT-qPCR.

Results

Lymphocytosis and the percentage of tumoral lymphocytes in chronic lymphocytic leukemia patients statistically correlate with a blocked autophagic flux.

Conclusion

Alterations in autophagic flux could play an important role in the physiopathology of chronic lymphocytic leukemia.
Literature
1.
2.
3.
Coll-Mulet L, Gil J. Genetic alterations in chronic lymphocytic leukaemia. Clin Transl Oncol. 2009;11:194–8.CrossRefPubMed
4.
Soderguist RS, Eastman A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Ther. 2016;15(9):2011–7.CrossRef
5.
Jain MV, et al. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med. 2013;17:12–29.CrossRefPubMedPubMedCentral
6.
Watanabe K, Tsubata T. Autophagy connects antigen receptor signaling to costimulatory signaling in B lymphocytes. Autophagy. 2009;5:108–10.CrossRefPubMed
7.
Bologna C, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Invest. 2016;126:181–94.CrossRefPubMed
8.
Kong YL, et al. Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course. Leuk Res. 2018;66:8–14.CrossRefPubMed
9.
10.
Stellrecht CM, et al. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017;179:266–71.CrossRefPubMedPubMedCentral
11.
12.
13.
Blunt MD, et al. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits micro environmental signaling in CLL and the Eµ-TCL1 mouse model. Blood. 2015;125:4032–41.CrossRefPubMed
14.
Metadata
Title
Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells
Authors
J.-R. Romero-Macías
R. Pascual-Serra
O. Roche
F. Ruiz-Marcos
A. Serrano-Martínez
P. González-Aguado
B. Belandia
M.-J. Ruiz-Hidalgo
R. Sánchez-Prieto
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02041-x

Other articles of this Issue 9/2019

Clinical and Translational Oncology 9/2019 Go to the issue

Research Article

Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma

Research Article

Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study

Research Article

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment

Research Article

Distinct prognostic values of Annexin family members expression in acute myeloid leukemia

Research Article

Differential expression of S1P receptor subtypes in human bladder transitional cell carcinoma

Research Article

Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits